Peritoneal neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Peritoneal neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Relacorilant, Nab-Paclitaxel, and Bevacizumab for Patients with Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer https://clinicaltrials.eu/trial/study-of-relacorilant-nab-paclitaxel-and-bevacizumab-for-patients-with-advanced-ovarian-peritoneal-or-fallopian-tube-cancer/ Wed, 29 Apr 2026 15:04:56 +0000 https://clinicaltrials.eu/trial/study-of-relacorilant-nab-paclitaxel-and-bevacizumab-for-patients-with-advanced-ovarian-peritoneal-or-fallopian-tube-cancer/ This clinical trial is focused on studying advanced forms of cancer, specifically epithelial ovarian cancer, primary peritoneal cancer, and fallopian-tube cancer. The study will explore the effects of a treatment combination that includes the medication relacorilant, also known by its code name CORT125134, along with nab-paclitaxel and bevacizumab. Relacorilant is taken orally in the form of a soft capsule, while nab-paclitaxel and bevacizumab are administered through intravenous infusion, which means they are given directly into a vein.

The purpose of this study is to evaluate how effective this combination of medications is in treating the specified types of cancer. Participants in the study will receive these medications and will be monitored over time to assess their response to the treatment. The study will track the progression of the disease and any changes in the participants’ health. The trial aims to gather information on how well the treatment works and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and assessments to monitor their health and the impact of the treatment. The study is designed to provide valuable insights into the potential benefits and risks of using relacorilant in combination with nab-paclitaxel and bevacizumab for treating these advanced cancers. This research could contribute to developing more effective treatment options for patients with these types of cancer in the future.

]]> Study of Relacorilant and Nab-Paclitaxel for Patients with Advanced, Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer https://clinicaltrials.eu/trial/study-of-relacorilant-and-nab-paclitaxel-for-patients-with-advanced-platinum-resistant-ovarian-fallopian-tube-or-peritoneal-cancer/ Wed, 29 Apr 2026 15:01:12 +0000 https://clinicaltrials.eu/trial/study-of-relacorilant-and-nab-paclitaxel-for-patients-with-advanced-platinum-resistant-ovarian-fallopian-tube-or-peritoneal-cancer/ This clinical trial is focused on studying a type of cancer known as advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer. The study is testing a new treatment that combines two medications: relacorilant and nab-paclitaxel. Relacorilant is also known by its code name CORT125134. Nab-paclitaxel is a form of chemotherapy that is often used to treat various types of cancer. The purpose of this study is to compare the effectiveness of the combination of relacorilant and nab-paclitaxel against nab-paclitaxel alone in treating this type of cancer.

Participants in the study will receive either the combination of relacorilant and nab-paclitaxel or nab-paclitaxel by itself. The treatment will be given over a period of 28 days, and the study will monitor how the cancer responds to the treatment. The study aims to see if the combination treatment can help control the cancer better than nab-paclitaxel alone. The study will also look at how long patients live without the cancer getting worse and other measures of how well the treatment works.

This trial is important for understanding if adding relacorilant to nab-paclitaxel can provide a new option for patients with this challenging type of cancer. The study will help determine if the combination treatment can improve outcomes for patients compared to the standard treatment with nab-paclitaxel alone. Participants will be closely monitored throughout the study to ensure their safety and to gather important information about the treatment’s effects.

]]>